The goal of the preclinical development process is to help you predict in-human efficacy. Far too often drugs fail late in the development stages because they are not effective enough. These late failures come with a high cost to the drug developers and missed opportunities to come to market with much needed therapies to enhance the quality of life for patients. Our approach is to design programs that provide data that is predictive and translatable to the clinic. Because your compound is unique, we take a customized approach in our partnerships. This may include in vitro mode of action, in vivo efficacy, and translational readouts to provide accurate and meaningful data that you can rely on for critical decisions.
In vitro assays provide drug developers the ability to study the mechanisms of action and evaluate proof of concept of their therapies. In neurological conditions, this requires in vitro techniques to study neuronal processes, synapse formation, or axonal degeneration. This provides valuable insight and understanding in cognition, learning, and degenerative diseases.
MD Biosciences offers in vitro synaptic imaging assay to study treatment effect on synapse formation. The neurite outgrowth assay provides an in vitro method to examine the potential effects of exogenous compounds on neuronal activity and development.
Rodent models are commonly used for evaluating therapeutic potential prior to clinical studies. MD Biosciences offers a range of in vivo efficacy models for the study of pain and degenerative diseases. Combined with behavior measurements and end-point measures, our rodent studies provide data needed to move your compound forward.
We realize the need to increase the translatability to the clinic requires models that accurately reflect the human condition. MD Biosciences has developed in vivo efficacy models in the pig that provide greater correlation to human. By utilizing translational models in larger species prior to going to clinical stages, drug developers can increase the success rates of those drugs entering clinical phases.
Click here to learn more about our translational models.